Outlook heads to regulators with eye-friendly Avastin

Roche’s cancer drug Avastin is already used off-label in wet age-related macular degeneration, and has shown similar efficacy to the group’s similarly acting eye drug, Lucentis. Outlook Therapeutics now hopes to make the use of Avastin’s active ingredient official in AMD.